CLRB - CIK 0001279704
The table below shows Cellectar Biosciences, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.35M | $12.55M | $11.04M | $13.91M | $34.26M | $25.87M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $9.27M |
| $13.62M |
| $12.62M |
| $14.89M |
| $35.90M |
| $27.91M |
| Property, plant & equipment | $339.70K | $595.27K | $647.55K | $700.83K | $910.13K | $978.70K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $11.12M | $14.63M | $13.70M | $16.04M | $37.29M | $29.38M |
| Accounts payable | - | - | - | - | - | - |
| Total current liabilities | $4.87M | $4.91M | $5.87M | $6.02M | $20.31M | $15.17M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $6.40M | $5.25M | $6.23M | $6.41M | $20.75M | $15.62M |
| Retained earnings | -$274.79M | -$263.84M | -$259.39M | -$253.95M | -$244.99M | -$230.32M |
| Total equity | $3.34M | $8.00M | $6.09M | $8.25M | $15.16M | $12.38M |